Kura Oncology Inc (KURA)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Troy E. Wilson
Employees:
120
3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO, CA 92121
(858) 500-8800

Kura Oncology, Inc. develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction. tipifarnib, an orally bioavailable inhibitor of farnesyl transferase, is in Phase II clinical trials for the. treatment of solid tumors and hematologic indications.

Data derived from most recent annual or quarterly report
Market Cap 908.56 Million Shares Outstanding66.61 Million Avg 30-day Volume 766.703 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.97
Price to Revenue0.0 Debt to Equity0.0 EBITDA-133.548 Million
Price to Book Value2.1774 Operating Margin0.0 Enterprise Value485.929 Million
Current Ratio17.636 EPS Growth-0.063 Quick Ratio17.287
1 Yr BETA 1.1369 52-week High/Low 19.93 / 10.41 Profit Margin0.0
Operating Cash Flow Growth-7.4427 Altman Z-Score17.7399 Free Cash Flow to Firm -97.958 Million
Earnings Report2023-02-23
View SEC Filings from KURA instead.

View recent insider trading info

Funds Holding KURA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding KURA

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2023-01-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-01-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-12:
    Item 8.01: Other Events
  • 8-K: filed on 2022-11-03:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-03:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 3.02: Unregistered Sales of Equity Securities
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-29:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-08-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-23:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BAIR TERESA BROPHY CHIEF LEGAL OFFICER

    • Officer
    0 2022-11-17 1

    SCHAFER CAROL

    • Director
    23,000 2022-06-21 1

    HASNAIN FAHEEM

    • Director
    23,000 2022-06-21 1

    MALLEY THOMAS

    • Director
    23,000 2022-06-21 1

    SZELA MARY T

    • Director
    23,000 2022-06-21 1

    STEIN STEVEN H

    • Director
    23,000 2022-06-21 1

    COLLINS HELEN LOUISE

    • Director
    23,000 2022-06-21 1

    PARKS DIANE L.

    • Director
    23,000 2022-06-21 1

    DOYLE THOMAS JAMES SVP, FINANCE & ACCOUNTING

    • Officer
    7,110 2022-02-07 2

    WILSON TROY EDWARD PRESIDENT AND CEO

    • Officer
    • Director
    495,000 2022-01-26 0

    GRASSO MARC CFO, CBO

    • Officer
    152,900 2022-01-26 0

    FORD KATHLEEN CHIEF OPERATING OFFICER

    • Officer
    194,035 2022-01-26 0

    FLOWERS KIRSTEN CHIEF COMMERCIAL OFFICER

    • Officer
    193,511 2022-01-26 0

    DALE STEPHEN CHIEF MEDICAL OFFICER

    • Officer
    297,900 2022-01-26 0

    HOFFMAN ROBERT

    • Director
    23,000 2021-06-22 0

    BASTA JAMES CHIEF LEGAL OFFICER

    • Officer
    0 2021-01-26 0

    MARTELL BRIDGET A ACTING CHIEF MEDICAL OFFICER

    • Officer
    No longer subject to file 2020-08-24 0

    GUALBERTO ANTONIO HEAD OF DEVELOPMENT & CMO

    • Officer
    339,973 2019-07-10 0

    NORTH ANNETTE SVP, GENERAL COUNSEL

    • Officer
    0 2019-01-22 0

    REN PINGDA SVP CHEMISTRY&PHARMA SCIENCES

    • Officer
    0 2019-01-22 0

    FARNAM JOHN CHIEF OPERATING OFFICER

    • Officer
    0 2019-01-22 0

    ECOR1 CAPITAL FUND QUALIFIED, L.P.

    • 10% Owner
    4,408,097 2018-12-17 0

    HENSON HEIDI CHIEF FINANCIAL OFFICER

    • Officer
    0 2018-01-24 0

    LIU YI CHIEF SCIENTIFIC OFFICER

    • Officer
    0 2018-01-24 0

    PAPPAJOHN JOHN PRESIDENT

    • Officer
    • Director
    • 10% Owner
    0 2015-03-06 0

    KINLEY MATTHEW P SECRETARY, CFO

    • Officer
    • Director
    • 10% Owner
    0 2015-03-06 0

    VASSILIOU ARGYRIS

    • 10% Owner
    No longer subject to file 2015-03-06 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    KURA ONCOLOGY INC KURA 2023-01-27 22:15:03 UTC 3.9119 0.4081 1400000
    KURA ONCOLOGY INC KURA 2023-01-27 21:45:04 UTC 3.9119 0.4081 1400000
    KURA ONCOLOGY INC KURA 2023-01-27 21:15:04 UTC 3.9119 0.4081 1400000
    KURA ONCOLOGY INC KURA 2023-01-27 20:45:03 UTC 3.9119 0.4081 1400000
    KURA ONCOLOGY INC KURA 2023-01-27 20:15:04 UTC 3.9119 0.4081 1400000
    KURA ONCOLOGY INC KURA 2023-01-27 19:45:03 UTC 3.9119 0.4081 1400000
    KURA ONCOLOGY INC KURA 2023-01-27 19:15:03 UTC 3.9119 0.4081 1400000
    KURA ONCOLOGY INC KURA 2023-01-27 18:45:04 UTC 3.9119 0.4081 1400000
    KURA ONCOLOGY INC KURA 2023-01-27 18:15:03 UTC 3.9119 0.4081 1400000
    KURA ONCOLOGY INC KURA 2023-01-27 17:45:03 UTC 3.9119 0.4081 1400000
    KURA ONCOLOGY INC KURA 2023-01-27 17:15:04 UTC 3.9119 0.4081 1400000
    KURA ONCOLOGY INC KURA 2023-01-27 16:45:03 UTC 3.9119 0.4081 1400000
    KURA ONCOLOGY INC KURA 2023-01-27 16:15:03 UTC 3.9119 0.4081 1400000
    KURA ONCOLOGY INC KURA 2023-01-27 15:45:03 UTC 3.9119 0.4081 1300000
    KURA ONCOLOGY INC KURA 2023-01-27 15:15:04 UTC 3.9119 0.4081 1300000
    KURA ONCOLOGY INC KURA 2023-01-27 14:45:04 UTC 3.9119 0.4081 1300000
    KURA ONCOLOGY INC KURA 2023-01-27 14:15:03 UTC 3.9119 0.4081 1300000
    KURA ONCOLOGY INC KURA 2023-01-27 13:45:03 UTC 3.9119 0.4081 1300000
    KURA ONCOLOGY INC KURA 2023-01-27 13:15:03 UTC 3.9119 0.4081 1300000
    KURA ONCOLOGY INC KURA 2023-01-27 12:45:03 UTC 3.9119 0.4081 1300000

    Current Active Short Positions

    Get more info on our International short position coverage here

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Enhanced Index Plus Fund KURA -20.0 shares, $-199.0 2020-03-31 N-PORT
    FundVantage Trust- Gotham Index Plus All-Cap Fund KURA -55.0 shares, $-547.25 2020-03-31 N-PORT

    Short Position History (International Only)

    Holder Net Short Position Position Date Origin
    Squarepoint Ops LLC Kura Sushi Inc. 0.69% 2019-08-15 UK
    Squarepoint Ops LLC Kura Sushi Inc. 0.58% 2019-09-02 UK

    Congressional Transactions Past 6-Months

    To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***
    Congress Person Party Chamber Filing Filing Date Transaction Date Security Type Owner Transaction Amount
    Hon. Christopher L. Jacobs republican House Filing 2023-01-10 2022-12-12 P $1,001-$15,000

    Elevate your investments